You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

CAR

Showing 26 - 50 of 2,767
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Solid Tumor Trial in Taichung (HLA-G-CAR.BiTE allogeneic ?d T cells)

Not yet recruiting
  • Solid Tumor
  • HLA-G-CAR.BiTE allogeneic γδ T cells
  • Taichung, Non-US, Taiwan
    China Medical University Hospital
Nov 27, 2023

Metastatic Pancreatic Carcinoma Trial in Providence (CAR2 Anti-CEA CAR-T cells)

Terminated
  • Metastatic Pancreatic Carcinoma
  • CAR2 Anti-CEA CAR-T cells
  • Providence, Rhode Island
    Roger Williams Medical Center
Jan 12, 2023

Non Hodgkin's Lymphoma Trial in Beijing (TRAC and Power3 Genes Knock-out Allogeneic CD19-targeting CAR-T cell (ATHENA CAR-T),

Not yet recruiting
  • Non Hodgkin's Lymphoma
  • TRAC and Power3 Genes Knock-out Allogeneic CD19-targeting CAR-T cell (ATHENA CAR-T)
  • +2 more
  • Beijing, China
  • +2 more
Aug 23, 2023

Advanced Solid Tumor Trial in Beijing (aPD1-MSLN-CAR T Cells)

Not yet recruiting
  • Advanced Solid Tumor
  • αPD1-MSLN-CAR T Cells
  • Beijing, China
    National Cancer Center Cancer Hospital Chinese Academy of Medica
Jul 13, 2023

Multiple Myeloma, New Diagnosis Tumor Trial in Hangzhou (BCMA CAR-T cells)

Recruiting
  • Multiple Myeloma
  • New Diagnosis Tumor
  • BCMA CAR-T cells
  • Hangzhou, Zhejiang, China
    The First Affiliated Hospital, College of Medicine, Zhejiang Uni
Jan 31, 2023

Relapsed/Refractory Diffuse Large B-cell Lymphoma and Multiples Myeloma Trial in Dresden (MDC-CAR-BCMA001 (BCMA directed CAR

Not yet recruiting
  • Relapsed/Refractory Diffuse Large B-cell Lymphoma and Multiples Myeloma
  • MDC-CAR-BCMA001 (BCMA directed CAR T-cells)
  • Dresden, Germany
    Technische Universität Dresden, NCT/UCC, Early Clinical Trial Un
Apr 19, 2023

Light Chain (AL) Amyloidosis Trial in Sacramento (NXC-201 CAR-T)

Not yet recruiting
  • Light Chain (AL) Amyloidosis
  • NXC-201 CAR-T
  • Sacramento, California
    University of California Davis Medical Center
Oct 19, 2023

Hematologic Malignancy, CAR-T Cell Therapy Trial in Boston (Educational Video Tool)

Active, not recruiting
  • Hematologic Malignancy
  • CAR-T Cell Therapy
  • Educational Video Tool
  • Boston, Massachusetts
    Massachusetts General Hospital
Jan 24, 2023

CD70-positive Advanced Urologic Tumors Trial in Shanghai (Anti-CD70 CAR-T cells)

Recruiting
  • CD70-positive Advanced Urologic Neoplasms
  • Anti-CD70 CAR-T cells
  • Shanghai, Shanghai, China
    Changhai Hospital
Aug 11, 2023

B-cell Acute Lymphoblastic Leukemia Trial (CD19-CAR_Lenti_ALLO)

Not yet recruiting
  • B-cell Acute Lymphoblastic Leukemia
  • (no location specified)
Oct 10, 2023

Solid Tumor Trial in Shenyang (Intravenous infusion anti-HER2-CAR-T cell)

Not yet recruiting
  • Solid Tumor
  • Intravenous infusion anti-HER2-CAR-T cell
  • Shenyang, Liaoning, China
    Phase I Clinical Trials Center Of The First Hospital of China Me
Oct 30, 2023

SLE (Systemic Lupus), Sjogren's Syndrome, Systemic Scleroderma Trial in Taiyuan (CD19 targeted CAR-T cells)

Recruiting
  • SLE (Systemic Lupus)
  • +4 more
  • CD19 targeted CAR-T cells
  • Taiyuan, Shanxi, China
    Shanxi Bethune Hospital
Sep 25, 2023

B-cell Acute Lymphoblastic Leukemia, B-cell Lymphoma, Diffuse Large B Cell Lymphoma Trial in Beijing (CD19/CD22-bispecific CAR-T

Recruiting
  • B-cell Acute Lymphoblastic Leukemia
  • +2 more
  • CD19/CD22-bispecific CAR-T cells
  • Beijing, Beijing, China
    Liang Wang
Oct 7, 2023

Gastric Cancer, Colon Cancer, Rectal Cancer Trial in Wuhu (CEA-targeted CAR-T cells)

Recruiting
  • Gastric Cancer
  • +7 more
  • CEA-targeted CAR-T cells
  • Wuhu, Anhui, China
    The First Affiliated Hospital of Wannan Medical College
Nov 9, 2023

Relapsed/Refractory Multiple Myeloma, Plasma Cell Leukemia Trial (CAR-T (CAR-GPRC5D))

Not yet recruiting
  • Relapsed/Refractory Multiple Myeloma
  • Plasma Cell Leukemia
  • CAR-T (CAR-GPRC5D)
  • (no location specified)
Feb 26, 2023

Hepatocellular Carcinoma Trial in Shanghai (CAR-GPC3 T cells)

Recruiting
  • Hepatocellular Carcinoma
  • CAR-GPC3 T cells
  • Shanghai, China
    Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong Universi
Jun 22, 2023

Pupillary Assessment to Predict CAR-T Related Neurotoxicity

Not yet recruiting
  • Neurotoxicity
  • NeurOptics® NPi®-300 Pupillometer
  • Houston, Texas
    MD Anderson Cancer Center
Nov 16, 2023

Multiple Myeloma Trial in Wuhan (Fludarabine + Cyclophosphamide + BCMA-GPRC5D CAR-T Cells)

Recruiting
  • Multiple Myeloma
  • Fludarabine + Cyclophosphamide + BCMA-GPRC5D CAR-T Cells
  • Wuhan, Hubei, China
    Union Hospital, Tongji Medical College, Huazhong University of S
Aug 11, 2023

Lymphoma Trial in Seattle (biological, other, procedure)

Not yet recruiting
  • Lymphoma
  • Immune Globulin Infusion (Human), 10% Solution
  • +5 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Jul 21, 2023

Acute Myeloid Leukemia Trial in Beijing, Shenzhen, Haikou (CLL-1, CD33, CD38 and/or CD123-specific universal CAR- T cells)

Recruiting
  • Acute Myeloid Leukemia
  • CLL-1, CD33, CD38 and/or CD123-specific universal CAR- T cells
  • Beijing, Beijing, China
  • +2 more
Aug 8, 2023

Diffuse Large B-cell Lymphoma Trial in Hangzhou (Metabolically Armed CD19 CAR-T cells)

Recruiting
  • Diffuse Large B-cell Lymphoma
  • Metabolically Armed CD19 CAR-T cells
  • Hangzhou, Zhejiang, China
    The first affiliated hospital of medical college of zhejiang uni
Nov 1, 2023

Systemic Lupus Erythematosus (SLE) Trial in Shanghai (anti-CD19 CAR NK cells (KN5501))

Recruiting
  • Systemic Lupus Erythematosus (SLE)
  • anti-CD19 CAR NK cells (KN5501)
  • Shanghai, China
    Changhai Hospital
Aug 25, 2023

Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma Trial (Pirtobrutinib, LV20.19 CAR T cells)

Not yet recruiting
  • Non Hodgkin Lymphoma
  • +5 more
  • (no location specified)
Aug 4, 2023

Solid Tumors Trial in Houston (Rimiducid, TROP2-CAR-NK Cells, Fludarabine phosphate)

Not yet recruiting
  • Solid Tumors
  • Houston, Texas
    M D Anderson Cancer Center
Sep 27, 2023

Recurrent Glioblastoma Multiforme Trial in Beijing (SNC-109 CAR-T Cells)

Recruiting
  • Recurrent Glioblastoma Multiforme
  • SNC-109 CAR-T Cells
  • Beijing, China
    Chinese PLA General Hospital
May 11, 2023